Page last updated: 2024-11-12

marinobufagenin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

marinobufagenin: an endogenous digitalis-like factor; a Na(+),K(+)-ATPase inhibitor and cardiotonic agent; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

marinobufagenin : A cardiotonic steroid secreted by the toad Bufo rubescens and other related species such as Bufo marinus. An endogenous Na/K-ATPase inhibitor, it is a vasoconstrictor with effects similar to digitalis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11969465
CHEBI ID146151
SCHEMBL ID1483986
MeSH IDM0247451

Synonyms (31)

Synonym
marinobufogenin
bufa-20, 14,15-epoxy-3,5-dihydroxy-, (3.beta.,5.beta.,15.beta.)-
5.beta.-bufa-20, 14,15.beta.-epoxy-3.beta.,5-dihydroxy-
nsc-234205
470-42-8
marcinobufagin
nsc234205
marinobufagin
5-beta-bufa-20,22-dienolide, 3-beta,5-dihydroxy-14,15-beta-epoxy-
3-beta,5-dihydroxy-14,15-beta-epoxy-5-beta-bufa-20,22-dienolide
marinobufagenin
nsc 234205
bufa-20,22-dienolide, 14,15-epoxy-3,5-dihydroxy-, (3beta,5beta,15beta)-
5beta-bufa-20,22-dienolide, 14,15beta-epoxy-3beta,5-dihydroxy-
MBG ,
(3beta,5beta,15beta)-3,5-dihydroxy-14,15-epoxybufa-20,22-dienolide
(3beta,5beta,14alpha,15beta)-3,5-dihydroxy-14,15-epoxybufa-20,22-dienolide
CHEBI:146151
3beta,5-dihydroxy-5beta,15beta-14,15-epoxybufa-20,22-dienolide
C20036
SCHEMBL1483986
3kbt25gv2b ,
unii-3kbt25gv2b
bufa-20,22-dienolide, 14,15-epoxy-3,5-dihydroxy-, (3.beta.,5.beta.,15.beta.)-
DTXSID5041063
Q6764468
5-[(1r,2s,4r,6r,7r,10s,11r,14s,16s)-14,16-dihydroxy-7,11-dimethyl-3-oxapentacyclo[8.8.0.02,4.02,7.011,16]octadecan-6-yl]pyran-2-one
CS-0034270
MS-26813
HY-N6574
AKOS040760543

Research Excerpts

Overview

Marinobufagenin (MBG) is a member of the bufadienolide family of compounds, which are natural cardiac glycosides found in a variety of animal species, including man. It has different physiological and biochemical functions but have a common action on the inhibition of the adenosine triphosphatase sodium-potassium pump.

ExcerptReferenceRelevance
"Marinobufagenin (MBG) is a member of the bufadienolide family of compounds, which are natural cardiac glycosides found in a variety of animal species, including man, which have different physiological and biochemical functions but have a common action on the inhibition of the adenosine triphosphatase sodium-potassium pump (Na+/K+-ATPase). "( New Insights on the Role of Marinobufagenin from Bench to Bedside in Cardiovascular and Kidney Diseases.
Andreucci, M; Bolignano, D; Carullo, N; Coppolino, G; D'Agostino, M; Fabiano, G; Michael, A; Musolino, M; Presta, P; Zicarelli, MT, 2023
)
2.65
"Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid involved in sodium pump inhibition."( Marinobufagenin inhibits glioma growth through sodium pump α1 subunit and ERK signaling-mediated mitochondrial apoptotic pathway.
Lan, YL; Lou, JC; Ma, XC; Wang, H; Wang, X; Xing, JS; Yu, ZL; Zhang, B; Zou, S, 2018
)
2.64
"Marinobufagenin (MBG) is an endogenous cardiotonic steroid (CTS) that inhibits the Na+/K+-ATPase. "( The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension.
Auer, S; Borzan, V; Cadamuro, J; Felder, TK; Grübler, MR; Haschke-Becher, E; Keppel, MH; März, W; Mrazek, C; Oberkofler, H; Pandis, M; Piecha, G; Pilz, S; Schwetz, V; Tomaschitz, A; Trummer, C; Verheyen, N, 2019
)
2.23
"Marinobufagenin (MBG) is a cardiotonic steroid that increases in the circulation in preeclampsia. "( Marinobufagenin regulates permeability and gene expression of brain endothelial cells.
Abbas, K; Abi-Ghanem, D; Berghman, L; Ing, NH; Kaushik, A; Puschett, JB; Riggs, PK, 2014
)
3.29
"Marinobufagenin (MBG) is an endogenous Na/K-ATPase inhibitor, a natriuretic and a vasoconstrictor. "( Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, is Reduced by a Monoclonal Antibody to Marinobufagenin.
Bagrov, AY; Fedorova, OV; Fishbein, KW; Grigorova, YN; Juhasz, O; Lakatta, EG; Zernetkina, V, 2016
)
2.08
"Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid that is involved in the inhibition of the sodium pump Na(+)/K(+)-ATPase. "( Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling.
Childs, EW; Horvat, D; Puschett, JB; Uddin, MN, 2009
)
3.24
"Marinobufagenin (MBG) is a cardiotonic steroid that is increased in preeclampsia. "( Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia.
Agunanne, EE; Horvat, D; Puschett, JB; Uddin, MN, 2012
)
1.82
"Marinobufagenin (MBG) is an endogenous inhibitor of the sodium pump Na(+)/K(+) ATPase, and increased plasma MBG is associated with hypertension, chronic renal failure and preeclampsia."( Marinobufagenin impairs first trimester cytotrophoblast differentiation.
LaMarca, HL; Morris, CA; Nagowa, T; Pettit, GR; Puschett, JB,
)
2.3
"Marinobufagenin (MBG) is a cardiotonic steroid of the bufadienolide class of compounds which has the ability to inhibit the ubiquitous enzyme, Na+/K+-ATPase, resulting in natriuresis. "( Marinobufagenin interferes with the function of the mineralocorticoid receptor.
Foster, E; He, Q; Huang, L; Puschett, JB; Smith, CL, 2007
)
3.23
"Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid that is involved in the inhibition of the sodium pump Na(+)/K(+)-ATPase. "( Marinobufagenin inhibits proliferation and migration of cytotrophoblast and CHO cells.
Danchuk, S; Glaser, SS; Horvat, D; Mitchell, BM; Morris, CA; Puschett, JB; Sullivan, DE; Uddin, MN, 2008
)
3.23
"Marinobufagenin (MBG) is an endogenous mammalian cardiotonic steroid involved in the inhibition of Na(+)/K(+)-ATPase. "( Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function.
Glaser, SS; Horvat, D; Mitchell, BM; Puschett, JB; Uddin, MN, 2008
)
2.04

Actions

ExcerptReferenceRelevance
"Marinobufagenin (MBG) promotes natriuresis via inhibition of renotubular Na/K-ATPase (NKA) and causes vasoconstriction via inhibition of vascular NKA. "( Age-associated increase in salt sensitivity is accompanied by a shift in the atrial natriuretic peptide modulation of the effect of marinobufagenin on renal and vascular sodium pump.
Bagrov, AY; Fedorova, OV; Kashkin, VA; Lakatta, EG; Zakharova, IO, 2012
)
2.03

Dosage Studied

ExcerptRelevanceReference
" The analysis of ouabain-resting membrane potential dose-response relationships in the presence and absence of hyperpolarizing concentration of acetylcholine (100 nM) suggests the existence of two pools of alpha 2 Na+, K(+)-ATPase with different affinities for ouabain."( [Role of the alpha2-isoform of Na+, K(+)-ATPase in the positive inotropic effect of ouabain and marinobufagenin in the rat diaphragm].
Drabkina, TM; Kravtsova, VV; Krivoĭ, II; Kubasov, IV; Prokof'ev, AV; Vashchinkina, EV; Vasil'ev, AN,
)
0.35
" The cardiotonic steroids ouabain, digoxin, and marinobufagenin all show an inverted U-shaped dose-response curve with inhibition of pumping at concentrations near their IC(50), while increasing Na/K ATPase activity at doses below their IC(50)."( Low-dose cardiotonic steroids increase sodium-potassium ATPase activity that protects hippocampal slice cultures from experimental ischemia.
Bergold, PJ; Oselkin, M; Tian, D, 2010
)
0.62
" Ex vivo, at 10 µg/mL concentration, which is consistent with the clinical dosing of Digibind administered previously in PE, DigiFab and Digibind as well as anti-MBG mAb (0."( DigiFab interacts with endogenous cardiotonic steroids and reverses preeclampsia-induced Na/K-ATPase inhibition.
Adair, CD; Bagrov, AY; Bzhelyansky, AM; Emelyanov, IV; Fedorova, OV; Frolova, EV; Ishkaraeva-Yakovleva, VV; Solodovnikova, NG; Zazerskaya, IE, 2012
)
0.38
" This review emphasizes the key role of analytical development for dosage methods of MBG in biofluids, in the emergence of future perspectives in the diagnostic and therapeutic fields of preeclampsia (e."( Analytical aspects of marinobufagenin.
Blankert, B; Demeyer, M; Gerbaux, P; Lenaerts, C, 2013
)
0.7
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitorAn EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9).
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
steroid hormoneAny steroid that acts as hormone.
epoxy steroidAny steroid whose structure includes an epoxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (152)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (5.92)18.2507
2000's65 (42.76)29.6817
2010's64 (42.11)24.3611
2020's14 (9.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.68 (24.57)
Research Supply Index5.11 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (3.13%)5.53%
Reviews19 (11.88%)6.00%
Case Studies1 (0.63%)4.05%
Observational0 (0.00%)0.25%
Other135 (84.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]